On September 24, on the sidelines of the UN General Assembly in New York, UNAIDS and the African Union Development Agency convened African ministers, global health leaders and private-sector representatives around a single question: what does Africa need in order to produce more of its own medicines and health technologies.
"Africa cannot remain at the back of the line when life-saving medicines exist," said UNAIDS Executive Director Winnie Byanyima, framing a discussion that ranged across long-acting HIV prevention medicines, mRNA vaccine platforms and newer, shorter tuberculosis treatments.
African Union member states covered by the African Continental Free Trade Area, the mechanism leaders pointed to for building a market large enough to support local production.
The obstacle isn't ambition, it's fragmentation
Several speakers converged on the same practical problem. Zambia's health minister said the continent's technical know-how has grown and political will is now a given. South Africa's deputy health minister pointed to Biovac's COVID-era manufacturing experience as proof that local production needs predictable demand, pooled procurement and investment to be sustainable, not just a factory. NEPAD's director general was blunter still: fragmented national markets limit the scale and predictability manufacturers need to justify investing at all.
This is a market-design problem before it is a factory problem
The tools named to fix that were institutional rather than industrial. The African Medicines Agency, meant to harmonize regulatory review across member states. The African Continental Free Trade Area, meant to let a manufacturer sell across borders without refiling in each one. And pooled procurement mechanisms, meant to aggregate demand into orders large enough to plan a production line around.
A regional manufacturer cannot amortize a production line against 54 separate small national markets. The AMA, AfCFTA and pooled procurement are, functionally, an attempt to turn those 54 markets into something closer to one, which changes the investment case for anyone considering African manufacturing partnerships.
What to watch
Watch how quickly the African Medicines Agency harmonizes review timelines across more member states, watch pooled procurement volumes as a leading indicator of real demand aggregation, and watch whether the South-South cooperation Brazil's health ministry referenced, alongside its own G20-era local production coalition, turns into actual technology-transfer agreements.
The gap between availability and access, a phrase used repeatedly in New York, is exactly the market-access problem Venturion exists to help close. Regional manufacturing only works commercially if the demand side, procurement, regulatory pathways and distribution partners, is aligned before the supply side scales.